Ignite Creation Date:
2025-12-24 @ 11:51 PM
Ignite Modification Date:
2025-12-25 @ 9:46 PM
Study NCT ID:
NCT05199051
Status:
RECRUITING
Last Update Posted:
2025-02-19
First Post:
2021-11-12
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults with FLT3-ITD Relapse/refractory (R/R) AML
Sponsor:
Centre Antoine Lacassagne
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-06-03
Start Date Type:
ACTUAL
Primary Completion Date:
2027-03-15
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-03-15
Completion Date Type:
ESTIMATED
First Submit Date:
2021-11-12
First Submit QC Date:
None
Study First Post Date:
2022-01-20
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-02-18
Last Update Post Date:
2025-02-19
Last Update Post Date Type:
ACTUAL